Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
09 août 2021 14h39 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat...